Inspire Medical Systems (INSP) shares plummeted 6.06% in pre-market trading on Tuesday, February 11, 2025, after multiple analysts lowered their price targets on the medical device company.
The sell-off was primarily driven by analysts revising down their expectations for the stock's future performance. Truist Securities cut its price target on INSP to $235 from $250, although it maintained a Buy rating. Meanwhile, Wells Fargo also reduced its price target on INSP to $195 from $198.
No other significant news or events were reported that could have triggered the sharp decline in INSP's stock price. The downward revisions in analysts' price targets appear to be the primary reason behind the pre-market plunge, as investors reacted negatively to the lowered expectations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。